Elixir Medical Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Elixir Medical is proud to have been named to Fast Company 's prestigious list of the World's Most Innovative Companies of 2025. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the economy. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 609 organizations across 58 sectors and regions.
'Elixir is working to tackle the biggest problems in coronary and peripheral artery treatment by disrupting the status quo with its innovative technologies. In the U.S., one person dies every 33 seconds from cardiovascular disease, with coronary artery disease (CAD)—the most common form—being the leading cause of death globally. For patients who undergo percutaneous coronary intervention (PCI), the primary treatment for CAD, up to 20% experience repeat adverse events within five years due to stent failures, which we find unacceptable,' said Motasim Sirhan, CEO of Elixir Medical.
Elixir's leading technology platform, the DynamX® bioadaptor, was designed to address the shortcomings of current PCI technologies such as drug-eluting stents and work toward a continued decrease in adverse event rates. By rethinking the way an implant could work adaptively with the body, Elixir developed the bioadaptor to have a unique mechanism of action that is designed to restore vessel motion and function without compromising the vessel's ability to heal naturally, intending to revolutionize patient care and set a new standard for coronary artery disease (CAD) treatment.
Data from two randomized clinical trials studying the bioadaptor demonstrate that by enabling the coronary implant to adapt to the vessel, artery hemodynamic modulation is restored, and PCI treatment outcomes can be further improved. Elixir received two FDA Breakthrough Device Designations in 2024 for the DynamX® Sirolimus-Eluting Coronary Bioadaptor System for CAD treatment and the DynamX® BTK System for peripheral use to treat chronic limb-threatening ischemia.
Elixir Medical is also working on LithiX Hertz Contact Intravascular Lithotripsy (IVL) System for calcium fragmentation in moderate to severe calcified coronary artery lesions during PCI procedure. Calcified lesions are associated with limited vessel expansion and contribute to increased adverse outcomes. Compared to other technologies for calcium modification, the LithiX Hertz Contact IVL System mechanism of action is based on the physics principle of Hertz Contact Stress and requires no energy source or capital equipment, positively impacting procedure workflow with short procedure times and a simpler learning curve, while delivering excellent clinical results.
The World's Most Innovative Companies stands as Fast Company 's hallmark franchise and one of its most anticipated editorial efforts of the year. To determine honorees, Fast Company' s editors and writers review companies driving progress around the world and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world.
'Our list of the Most Innovative Companies offers both a comprehensive look at innovation today and a playbook for the future,' said Fast Company editor-in-chief Brendan Vaughan. 'This year, we recognize companies that are harnessing AI in deep and meaningful ways, brands that are turning customers into superfans by overdelivering for them, and challengers that are introducing bold ideas and vital competition to their industries. At a time when the world is rapidly shifting, these companies are charting the way forward.'
The full list of Fast Company's Most Innovative Companies honorees can now be found at fastcompany.com. It will also be available on newsstands beginning March 25.
Fast Company will host the Most Innovative Companies Summit and Gala for honorees on June 5. The summit features a day of inspiring content, followed by a creative black-tie gala including networking, a seated dinner, and an honoree presentation.
ABOUT ELIXIR MEDICAL
Elixir Medical Corporation, a privately held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheral artery disease. Our transformative technologies have multiple applications across the cardiovascular space capable of delivering improved clinical outcomes for millions of patients. Visit us at www.elixirmedical.com and on LinkedIn and X. The DynamX Sirolimus Eluting Coronary Bioadaptor System is an investigational device. Limited by Federal (or United States) law to investigational use. The LithiX IVL System is not approved for sale in the U.S.
ABOUT FAST COMPANY
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with fellow business publication Inc. For more information, please visit fastcompany.com.
.
CONTACT: Richard Laermer
RLM PR
(212) 741-5106 X 216
SOURCE: Elixir Medical
Copyright Business Wire 2025.
PUB: 03/18/2025 10:47 AM/DISC: 03/18/2025 10:47 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
10 hours ago
- CNBC
Pixar exec who worked for Steve Jobs: Apple co-founder had one skill that made him great—and one habit to avoid
Steve Jobs knew he wasn't an expert in filmmaking — even after funding a spinout of animation studio Pixar, which was originally division of production company Lucasfilm, in 1986. Jobs was "pretty amazing at saying, 'this is not my business,'" chief creative officer at Pixar, Pete Docter, said at Fast Company's Most Innovative Companies Gala and Summit on Thursday. Jobs' attitude was "I'm not going to come in here and direct this movie or tell you what to do," Docter said. As a 35-year employee of the company, Docter got to witness the Apple co-founder operate up close. Here's one leadership strength Docter noticed in Jobs — and one habit he hopes never to adopt himself. One skill Jobs had was being able to distill a conversation down to its essence and deliver the core idea succinctly. "He could walk into rooms where he knew nothing about what was going on," Docter said, "sit for about five minutes and analyze what the conversation was really about." And that made it easier for Jobs to help employees solve problems. "I think that came from years of practicing," said Docter. "That it's not something anyone's really born with." It's a skill he's tried to improve himself. One thing Jobs wasn't great at, said Docter, was respecting people's personal time. "He would call — especially the producers — at any time, day or night, 3 in the morning, you're on vacation, doesn't matter," Docter said. "He wants to talk to you about it, you're on." Docter assumes this habit came from Jobs' passion for what he was doing. Still, it's not a practice he wants to employ. In his capacity as a leader at Pixar, he's trying not to call people at all hours of the night but "I still email people" outside of business hours, he said. "I guess that's what my wife's trying to get me to stop doing," he said.
Yahoo
a day ago
- Yahoo
Waymo is winning in San Francisco
The self-driving car service Waymo has been active in San Francisco for 20 months and has already captured 27% of the city's rideshare market, according to new research compiled by Mary Meeker's Bond venture capital firm. That rapid progress suggests the mainstreaming of self-driving car service could happen faster than once thought. Why you're catching the 'ick' so easily, according to science Waymo is winning in San Francisco Supersonic air travel gets green light in U.S. after 50-year ban lifted 'What we've done in San Francisco is prove to ourselves—and to the world—that not only does autonomy work, but it works at scale in a market and can be a viable commercial product,' Waymo Co-CEO Dmitri Dolgov told Fast Company in March. In my experience as a frequent Waymo user, the service can cost up to a third more than Uber, depending on demand. But in some ways it's worth it. While Uber was originally meant to make ridesharing a friendlier and more social experience than taxi service, being alone can have its perks, too. A Waymo One ride can be a time of quiet contemplation, or even meditation, slotted in between meetings or other tasks. With Uber or a taxi service, you also get a different experience each time. The quality, condition, and odor of the vehicle varies from ride to ride, as does the driver's level of sociability, attitude, behavior, and language. Waymo service, by contrast, is largely the same every time: same Jaguar SUV, same neutral smell, same mellow, ambient music (which you can shut off if you want to). Note that Waymo's Jaguar I-PACE SUVs, after being decked out in computers and sensors, probably cost between $130,000 and $150,000, Motor Trend estimates. So Waymo could adopt less-expensive, and less-posh, vehicles as it scales to drive down costs. Riders may feel more in control in a self-driving car (sounds counterintuitive, I know). In an Uber, 'my car, my rules' governs a number of aspects of the ride. I wouldn't ask an Uber driver to change or turn off the music in his own car, for example. In a Waymo 'you control the music and don't feel judged by being on a call or whatever you do,' Das tells Fast Company. And while Waymo rides may take a little longer than Uber rides to get to their destination, there's evidence that Waymo rides are safer than human-driven cars. Waymo researchers studied more than 56.7 million miles of driving and found that by removing the human driver Waymo achieves a 92% reduction in crashes involving injuries among pedestrians, an 82% reduction in crashes with cyclists, and an 82% reduction in crashes involving motorcyclists. Yes, Waymo might have captured a quarter of the market here because San Francisco is a tech city. 'This may be due to a combination of the region's tech-focused culture, busy workers staying heads-down on work or sensitive calls, or simply a preference for fewer social interactions,' Jeremiah Owyang of Blitzscaling Ventures tells Fast Company. 'Standardized quality in a private setting is outperforming a variable, faster human driver—a physical representation of automation.' And don't get me wrong. I've had my share of problems with Waymo. On at least two occasions, in less-traveled parts of the city, a Waymo car has dropped me off several blocks from my destination. And, at least in San Francisco, you still can't take a Waymo to the airport (the company started servicing its first airport, Phoenix Sky Harbor, in 2022). Still, the differences that matter between the self-driving and human-driven experiences are becoming clearer to more consumers. And some of the ones that really matter seem to favor Waymo. Waymo currently offers rides in the San Francisco Bay Area and down the peninsula and Silicon Valley. The state of California just gave it permission to offer rides in San Jose. The company, which spun off from parent Google 10 years ago, also operates in Los Angeles, Phoenix, and Austin. Across these markets, Waymo says its cars have covered more than 33 million miles. In Austin, Waymo operates through a partnership with Uber. Riders hail a self-driving car through the Uber app. Within its 37-square-mile service area in Austin, Waymo accounts for nearly 20% of Uber rides. Waymo was valued at $45 billion after its most recent funding round of $5.6 billion last October. The company reports its revenue under parent company Alphabet's 'Other Bets' category, which showed $450 million in revenue and an operating loss of $1.2 billion for the first quarter of 2025. This post originally appeared at to get the Fast Company newsletter: Sign in to access your portfolio
Business Upturn
a day ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
